Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Coeptis Therapeutics Holdings Equity Warrants Exp 31st Oct 2025 COEPW

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is focused on developing cell therapy platforms for cancer. The Company's product portfolio and rights are highlighted by a universal, multi-antigen chimeric antigen receptor (CAR)-T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK) and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the Company is developing with VyGen-Bio and medical researchers at the Karolinska Institute. Its CAR therapy is a treatment for cancer in which a patient's T cells (a type of immune cell) are genetically engineered to recognize cancer cells to target and destroy them. Its CAR T therapies are revolutionizing the treatment of many blood cancers, including B cell leukemias and lymphomas by targeting specific proteins found in these cancers.


NDAQ:COEPW - Post by User

Coeptis Therapeutics Holdings Equity Warrants Exp 31st Oct 2025
Bullboard Posts
User Avatar Image
(9)
•••
Post by MikeTesteron Aug 01, 2024 7:42pm
22 Views
Post# 36159554

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEPW): Navigati

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEPW): Navigatihttps://beyondspx.com/2024/08/01/coeptis-therapeutics-holdings-inc-nasdaqcoepw-navigating-the-challenges-of-a-biopharmaceutical-startup/
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities